Comparison matrix paper 3
Details:
The culmination of the doctoral journey is the dissertation. This assignment will provide an opportunity to research possible topics in the field of leadership that could be used for your dissertation research.
General Requirements:
Use the following information to ensure successful completion of the assignment:

• Instructors will be using a grading rubric to grade the assignments. It is recommended that learners review the rubric prior to beginning the assignment in order to become familiar with the assignment criteria and expectations for successful completion of the assignment.
• Doctoral learners are required to use APA style for their writing assignments. The APA Style Guide is located in the Student Success Center.
• This assignment requires that at least two additional scholarly research sources related to this topic, and at least one in-text citation from each source be included.
• Locate and print “Comparison Matrix 2.”
• Locate and print “Empirical Research Checklist.”
• Go to the GCU Library. Use the “Find Journal Articles” search feature found on the home page of the GCU Library to locate three scholarly empirical research sources related to leadership. Use the “Empirical Research Checklist” to determine if a study is empirical. One of the three sources must be related to the role personality plays in leadership. One may be on any topic related to leadership. The third must come from the reference list of one of the two previously chosen empirical sources.
• Use information from the empirical sources to complete “Comparison Matrix 2.”

Directions:
Use the information from the completed “Comparison Matrix 2” to write a paper of 1,250-1,500 words that summarizes the three scholarly empirical research sources and proposes at least one dissertation research study you might pursue. The paper will include the following sections:
Introduction (200-250 words)

1. The title of each study
2. The author of each study
3. Comparison of the purposes of each study
4. Comparison of the author’s statements of why the study is important.

Research Questions (250-300 words)

1. Comparison of the research questions posed in the studies

Sample Populations (175-225 words)

1. Comparison of the sample populations used in the studies

Results (300-350 words)

1. Comparison of the results of the studies

Conclusion (325-375 words)

1. Discussion of the limitations of the studies
2. Discussion of what you conclude from the studies
3. Proposal of at least one dissertation research study you might pursue and how choosing this possible topic will generate new knowledge in this field of study

Submit the completed “Comparison Matrix 2” and the “Research Study Paper” as a single deliverable.
LDR802.v10R.EmpiricalResearchChecklist_Student.docxLDR802.v10R.ComparisonMatrix2_Student.docx

Medication Insulin Lispro
Due July 2, 2017
Document APA Format
Note any additional references used
(See Attached information from the FDA-Food & Drug Administration)
Include information in the paper that is in Bold
(see information noted from my initial research)
Pharmacokinetics of Lispro
(Information to use) Used in management of Diabetes mellitus, types 1 and 2: Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control
Onset of action
Peak
Rapid acting: insulin lispro (Humalog)
              0 to 15 minutes (Peak)
30 to 90 minutes (Onset of Action)
Half-life
Duration of action
Pharmacodynamics of Lispro insulin
Pharmacotherapeutics of Lispro
Include Drug-to-drug interactions,
Drug-to-food interactions,
Drug-to-herb interactions
Routes and dosage ranges
For Children
For Adults
(Information to consider in writing paper)
Type 1 Diabetic : Note: Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the total units/kg/day of all insulin formulations combined.
Initial total insulin dose: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.
Usual maintenance range: 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:
Nonobese: 0.4 to 0.6 units/kg/day
Obese: 0.8 to 1.2 units/kg/day
Adverse effects of Lispro
·       Cardiovascular: Peripheral edema
·       Central nervous system: Headache (type 1 diabetes: 30%; type 2 diabetes: 12%), pain (11% to 20%)
·       Endocrine & metabolic: Hypoglycemia, hypokalemia, weight gain
·       Gastrointestinal: Diarrhea (type 1 diabetes: 9%), nausea (type 1 diabetes: 6%)
·
·       Genitourinary: Urinary tract infection (type 1 diabetes: 6%)
·
·       Hypersensitivity: Hypersensitivity reaction
·
·       Immunologic: Antibody development
·
·       Infection: Infection (10% to 14%)
·
·       Local: Hypertrophy at injection site, injection site reaction, lipoatrophy at injection site
·
·       Neuromuscular & skeletal: Myalgia (type 1 diabetes: 7%; most likely secondary to excipient metacresol)
·
·       Respiratory: Flu-like symptoms (type 1 diabetes: 35%; type 2 diabetes: 6%), pharyngitis (type 1 diabetes: 33%; type 2 diabetes: 7%), rhinitis (type 1 diabetes: 25%; type 2 diabetes: 8%)
• Glycemic control: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content or timing of meals), changes in the level of physical activity, increased work or exercise without eating or changes to co-administered medications. Hyperglycemia is also a concern; may occur with CSII pump or infusion set malfunctions or insulin degradation; hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type or administration method. Use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long standing diabetes, diabetic nerve disease, patients taking beta-blockers or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.
• Hypersensitivity: Hypersensitivity reactions (serious, life-threatening and anaphylaxis) have occurred. If hypersensitivity reactions occur, discontinue administration and initiate supportive care measures.
• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use).
Monitoring
·       Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.
Patient teaching